Teva Pharmaceutical Industries (TEVA) Total Debt (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Total Debt for 18 consecutive years, with $16.6 billion the latest figure, recorded in Q1 2026.

• Quarterly Total Debt changed 0.14% year-over-year to $16.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.6 billion (changed 0.14% YoY) and the FY2025 annual result came in at $16.8 billion, down 5.49% from the prior year.
• Total Debt retreated to $16.6 billion in Q1 2026 per TEVA's latest filing, from $16.8 billion in the prior quarter.
• Over the last five years, Total Debt for TEVA reached as high as $22.9 billion in Q1 2022 and fell as low as $16.6 billion in Q1 2026.
• A 5-year average of $19.3 billion and a median of $19.6 billion in 2024 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2025 — Total Debt slipped 15.24% — and 2026, when it fell 0.14%.
• Year by year, Total Debt stood at $21.2 billion in 2022, then slipped by 6.5% to $19.8 billion in 2023, then slipped by 10.34% to $17.8 billion in 2024, then slipped by 5.49% to $16.8 billion in 2025, then slipped by 1.07% to $16.6 billion in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $16.6 billion, $16.8 billion, and $16.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.